ZOLL Medical led the financing round in which all of Respicardia's existing major investors participated.

CSA is a serious breathing disorder, which interrupts the normal breathing pattern during sleep and impacts quality of life and overall cardiovascular health.

Respicardia’s remede system is a transvenous implantable neurostimulation system, which induces the phrenic nerve and involves the diaphragm to restore a normal breathing pattern during sleep in patients with CSA.

In October this year, the remede system secured approval from the US Food and Drug Administration (FDA).

The approval was based on results pivotal trial, which showed transvenous neurostimulation with the remede system can decrease the severity of CSA, improve sleep, quality of life and patient satisfaction.

Respicardia’s trial is a prospective, multicenter and randomized controlled study designed to assess the safety and effectiveness of transvenous phrenic nerve stimulation using the remede system in patients with moderate to severe CSA.

The company intends to commercialise the remede system in the US.

Respicardia president and CEO Bonnie Labosky said: "We believe the remede system will soon become the treatment of choice for patients suffering from central sleep apnea and are pleased to receive significant funding from ZOLL in support of this important mission.

"Proceeds from the financing will be used to fund our U.S. commercialization efforts and support ongoing development of the system."

Zoll CEO Jonathan Rennert said: "The remede System is a breakthrough technology that uniquely treats the devastating effects CSA has on a person's quality of life and cardiovascular health.”

Image: Respicardia’s remede system will be used to treat central sleep apnea. Photo: courtesy of David Castillo Dominici / FreeDigitalPhotos.net.